Microscope and equipment showing new Vaccines Manufacturing Innovation Centre

First diagnostic saliva test for malaria to launch

ERADA Technology Alliance Ltd (ERADA) has announced the imminent launch of a ground-breaking diagnostic saliva test for malaria. The saliva-based diagnostic tool, to be marketed...

Lynparza is approved by FDA for advanced ovarian cancer

AstraZeneca and MSD announce Lynparza is approved by FDA for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. AstraZeneca and MSD...
Dengvaxia®, Sanofi's dengue vaccine.

Dengvaxia ® vaccine approved for dengue prevention in Europe

The European Commission has granted marketing authorisation for Dengvaxia ®, Sanofi's dengue vaccine. The marketing authorisation follows the October 18, 2018, recommendation by the European...
Amryt announces the results of an unblinded interim efficacy analysis on its pivotal Phase III EASE trial for AP101 for EB.

Almirall releases results of onychomycosis phase III trial of P-3058

Almirall announces that the pivotal study for P-3058 has met the primary endpoint in an onychomycosis phase III trial.  Almirall, S.A (ALM) has announced that...
Any closure at Ashton-Under-Lyne facility would affect approximately 140 Recipharm employees.

Recipharm explores ending operations in Ashton-under-Lyne facility

Recipharm is to initiate a process to explore the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK. The decision to initiate...
GSK and Pfizer to merge consumer healthcare

BREAKING NEWS: GSK and Pfizer to merge consumer healthcare

GSK and Pfizer to merge consumer healthcare in a Joint Venture announced this morning. This lays the foundation for separation of GSK to create...
New partnership for health innovation

Social & commercial network to enhance health innovation

University of Brighton researchers are joining forces with entrepreneurs and community groups to turn Brighton and Hove into a focal point for health innovation...
NICE recommends new treatment for unresectable or metastatic melanoma

BMS & Boston Medical Center announce research collaboration

BMS & Boston Medical Center enter research collaboration to investigate markers of immuno-oncology response and resistance Bristol-Myers Squibb Company...
Syringe with liquid

EC approves KEYTRUDA® as adjuvant therapy

MSD (Merck in the U.S. and Canada) has announced that the European Commission has approved its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment...
Rubraca receives CHMP positive opinion for ovarian cancer

Rubraca receives CHMP positive opinion for ovarian cancer

Clovis Oncology announces that Rubraca receives CHMP positive opinion recommending an additional indication for ovarian cancer.  Clovis Oncology, Inc. has announced that the European Unions (EU) European...

Latest articles

IMBRUVICA® misses primary endpoint in pancreatic cancer trial

IMBRUVICA® misses primary endpoint in pancreatic cancer trial

AbbVie have released an update on the RESOLVE trial of IMBRUVICA® in combination with chemotherapy agents in metastatic pancreatic cancer.  AbbVie, a research-based global biopharmaceutical company,...
Star Europe reports positive client and candidate feedback.

Star Europe’s Amsterdam office off to positive start

Star Europe has reported good feedback in the Netherlands since opening its Amsterdam office in November. Supported by established resources and infrastructure, the team at...
ORKAMBI® for cystic fibrosis

EC approves Vertex’s ORKAMBI® for cystic fibrosis patients

Vertex Pharmaceuticals announces that the European Commission has granted approval of the label extension for ORKAMBI® for cystic fibrosis patients.  The European Commission has granted approval...